AFM13 clinical trials
Also written AFM13.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses AFM13 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AFM13
- 7
Studies by the year they started
7 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
Affimed GmbH (4) · M.D. Anderson Cancer Center (1) · Ahmed Sawas (1) · University of Cologne (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses AFM13 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin LymphomasCompletedPhase 1/2M.D. Anderson Cancer CenterNCT04074746Written as Anti-CD30/CD16A Monoclonal Antibody AFM13
- Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLTerminatedPhase 2Affimed GmbHNCT05883449Written as AFM13
- Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis FungoidesCompletedPhase 2Affimed GmbHNCT04101331Written as AFM13
- AFM13 in Relapsed/Refractory Cutaneous LymphomasCompletedPhase 1/2Ahmed SawasNCT03192202Written as AFM13
- GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedPhase 2University of CologneNCT02321592Written as AFM13
- Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedPhase 1Affimed GmbHNCT02665650Written as AFM13
- A Study to Assess AFM13 in Patients With Hodgkin LymphomaCompletedPhase 1Affimed GmbHNCT01221571Written as AFM 13
Codes
What other systems call AFM13 · ClinicalTrials.gg INT001970
- MeSH (NLM) C000723551AFM13One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723551 | AFM13 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.